Status:
COMPLETED
Telmisartan and Losartan in Hypertensive IGT
Lead Sponsor:
Medical University of Graz
Conditions:
Hypertension
Impaired Glucose Tolerance
Eligibility:
All Genders
40-75 years
Phase:
PHASE4
Brief Summary
Inhibition of RAS delays onset of diabetes in clinical studies. Preliminary evidence suggests that telmisartan may have unique metabolic properties compared to other ARB due to activation of PPARγ. T...
Detailed Description
Background: Both, ACE-inhibitors as well as angiotensin-II-type-1 (AT1) receptor antagonists seem to reduce the development of type-II diabetes in patients with hypertension and/or high vascular risk ...
Eligibility Criteria
Inclusion
- IGT according the criteria of the WHO
- standardised office blood pressure \> 140/90 mmHG or treated hypertension
- 40 - 75 years of age
- signed informed consent
Exclusion
- known hypersensitivity towards telmisartan or losartan
- concommitant treatment with ACE-inhibitors
- BMI \> 35 kg/m2
- inability to perform self-control of blood pressure
- acute coronary syndrome or cerebrovascular event within the last 3 months
- Revascularisation within the last 3 months
- heart failure \> NYHA 2
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00407862
Start Date
January 1 2005
End Date
June 1 2006
Last Update
December 5 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Graz
Graz, Austria, 8036